It’s a Ph1 Aurora A/B/C inhibitor for ‘solid tumors’. Seems likely to be a member of one of the phthalazine series’ WO/2008/124083, WO/2008/057280, WO/2007/100646, or WO/2007/087276.
Archive for June, 2009
TAK-901
Posted by kinasepro on June 18, 2009
TAK-901 is Takeda’s ph1 Aurora B kinase inhibitor & US20090156557 suggests its:
Posted in Aurora, Takeda | 7 Comments »
PH-797804
Posted by kinasepro on June 9, 2009
In Ph2 for COPD & it’s an atropisomer…(biochem)
Who wants to guess if its R or S
Process App: 20080177077
Backup: 20080269264
Posted in p38, Pfizer | 6 Comments »
Off Targets
Posted by kinasepro on June 9, 2009
Just when you thought this stuff was easy… Turns out:
* Gleevec & Nilotinib hit ‘α-carbonic anhydrase‘ (wiki). (not to mention p38ß)
* Sorafenib hits P38 (new structure),
* GW-5074 (cRaf inhibitor) weakly hits glutamate dehydrogenase (~2uM, new structure, wiki).
Posted in General Interest | Leave a Comment »
Toceranib
Posted by kinasepro on June 3, 2009
aka Palladia, PHA-291639, & SU11654 got its FDA Approval today! Well… In dogs at least:. It’s for canine mast cell tumors.
yeh, its the pyrrolidine version of Sutent & its the phosphate salt
Posted in Approved, Pfizer | 8 Comments »
MK n AZ
Posted by kinasepro on June 2, 2009
Two allosteric inhibitors are better then one!
AZD-6244 is Array’s MEK inhibitor [ARRY-886] which failed a solo ph2 endpoint not too long ago.
MK-2206 is Merck’s ph1 AKT inhibitor
Posted in Array, Astra, Merck & Co. | Leave a Comment »
